Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

• Source: Shutterstock

Day One Biopharmaceuticals, Inc. is making an aggressive push to commercialize Ojemda (tovorafenib) following its US Food and Drug Administration accelerated approval for children with pediatric low-grade glioma (pLGG), the most common form of brain tumor in children, and intends to target the vast majority of an addressable population in the low thousands.

The FDA approved Ojemda, a type II RAF inhibitor, on 23 April for patients aged 6 months and older with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip